Developer docs
API playgroundTry for free, no card

Search company profiles

Extracellular

Full company profile

uuid0002v1u

Namestring
Extracellular
Legal namestring
Extracellular
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Extracellular is a Bristol, UK-based contract development and manufacturing organization (CDMO) founded in 2021 by Will Milligan, dedicated to supporting the cellular agriculture industry through bioprocessing and scale-up services for animal and plant cell-cultivated products. The company serves startups and enterprises developing cultivated meat, seafood, plant-cell-derived ingredients (cocoa, coffee, saffron), cosmetics actives (cell lysate, exosomes), and bio-materials (cultivated leather, cotton, wood), addressing the 'valley of death' between R&D and commercial production by eliminating the need for customers to build their own pilot facilities. Its technology platform combines proprietary continuous perfusion and repeated fed-batch processes delivering industry-leading 380g/L+ yields, a high-throughput screening platform capable of evaluating up to 1,000 media or cell conditions, and parallel bioreactor optimization using 12-24 units to compress process development timelines.

The company operates Europe's largest dedicated contract pilot facility for cell-cultivated products at its 9,000 ft² Bristol site within the Science Creates incubator, with bioreactor capacities ranging from 50L to 2,000L and planned expansion to 8,000L total capacity (up to 100 tons/year). Extracellular holds ISO 22000 food safety management, ISO 9001:2015 quality management, and Cyber Essentials Plus certifications, and is registered as a UK Food Business with the FSA and FSS, enabling regulated taste trials for novel cell-cultivated foods. Revenue is generated through five service lines (Contract Manufacturing, Process Development, Media Development, Cell Line Development, and Consultancy) sold via direct enterprise sales on a quote-based, multi-year contract pricing model. The company has served 20+ customers across 8 countries and 4 continents, with named engagements including Merck Life Science and Meatly, and is supported by strategic partnerships with Big Idea Ventures, Vevolution, Roslin Technologies, Nutreco, and Innovate UK.

Short descriptiontext

Extracellular is a Bristol-based CDMO providing bioprocessing and scale-up services for cell-cultivated meat, seafood, plant cell ingredients, cosmetics, and bio-materials companies, operating Europe's largest dedicated pilot facility to bridge R&D and commercial production.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBristol, United Kingdom
HQ citystring
Bristol
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cultivated meat CDMO, bioprocessing services, cell line development, media optimization services, contract manufacturing
Industry2 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • General Industrial Machinery & Equipment, Nec3569
Product category
Bioprocessing CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Contract Manufacturing
TypeManaged Services
Description

Scale-up and contract manufacturing services up to 2,000L bioreactor scale within purpose-built food-grade facilities. Customers pay for manufacturing capacity and production services.

extracellular.com
2Process Development Services
TypeProfessional Services
Description

Optimization and scale-up of manufacturing processes using plant and animal cells. Includes parallel bioreactors for high-throughput optimization, process intensification, and scalability studies.

extracellular.com
3Media Development Services
TypeProfessional Services
Description

High-throughput media optimisation for cost, quality and regulatory compliance, including serum replacement and cost optimization studies.

extracellular.com
4Cell Line Development Services
TypeProfessional Services
Description

Established workflows for adherent and suspension cell lines including cell isolation, monoclonal cell lines, cell banking, and suspension adaptation.

extracellular.com
5Consultancy Services
TypeProfessional Services
Description

Technology assessment, manufacturability and cost modelling for novel bio-based products including commercial strategy, technology landscape analysis, and due diligence support.

extracellular.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing for CDMO services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing dependent on project scope, bioreactor scale (up to 2,000L), duration, and specific service requirements. No public pricing tiers available.

extracellular.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Extracellular is a contract development and manufacturing organisation (CDMO) providing bioprocessing and scale-up services for cell-cultivated products. The company offers five core service lines — Contract Manufacturing (up to 2,000L bioreactor scale), Process Development, Media Development, Cell Line Development, and Consultancy — targeting cultivated meat, seafood, plant cell culture, cosmetics, and bio-materials companies. All services are delivered from purpose-built food-grade facilities in Bristol, UK.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 70% reduction in costs and timelines for media scaling projects (200L scale in 5 months)
+3 more records
Product overview1 text field

Extracellular is a CDMO (contract development and manufacturing organisation) offering five interconnected service lines covering the full product development lifecycle. The three development-focused services—Process Development, Media Development, and Cell Line Development—handle R&D projects across cell-line development, media optimization, and process engineering. The two commercial-stage services—Contract Manufacturing and Consultancy Services—provide infrastructure and expertise for production at scale and strategic guidance on market entry. All services support the company's three market focus areas: Food & Nutrition (cultivated meat, seafood, plant cell culture), Personal Care & Cosmetics (plant cell derived ingredients), and Materials (cultivated leather, cotton, wood). The company operates purpose-built facilities in Bristol, UK, with bioreactor capabilities from 1L to 2,000L.

Product and service5 records
1Contract Manufacturing
CategoryContract manufacturing services
Description

Scale-up and contract manufacturing services up to 2,000L within purpose-built facilities, providing commercial production, material supply for product evaluation, and scalability validation for cell-cultivated product companies in food, cosmetics, and materials sectors.

2Process Development
CategoryProcess development services
Description

Optimization and scale-up of manufacturing processes using plant and animal cells, featuring parallel bioreactors for high-throughput optimisation, process intensification, and support for continuous, semi-continuous, and fed-batch processes.

3Media Development
CategoryMedia development services
Description

High-throughput media optimisation for cost, quality and regulatory compliance, including high-throughput screening, animal serum component replacement, cost optimisation, and media stability studies for cell-cultivated products.

4Cell Line Development
CategoryCell line development services
Description

Established workflows for adherent and suspension cell lines to optimize growth and productivity, including cell isolation, monoclonal cell lines, cell banking, and suspension adaptation for cultivated meat and other cell-cultivated products.

5Consultancy Services
CategoryStrategic consultancy services
Description

Technology assessment, manufacturability and cost modelling for novel bio-based products, including commercial strategy, cost of goods modelling, technology landscape analysis, and due diligence support for companies developing cell-cultivated products.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-presenting at the 2025 NAPIC Inaugural Conference on process innovations. Collaboration includes developing scalable, robust production platforms for cell cultivated products leveraging continuous perfusion and repeated fed-batch processes. Joint poster presentation showcasing complementary approaches to scalable manufacturing.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic partnership to scale Merck's serum-free media formulation to 200L using fed-batch process. Successfully produced kilograms of cultivated meat, demonstrating both Merck's high-performance media and Extracellular's pilot scale capabilities. Partnership highlighted at MEVO Conference 2024 in Barcelona.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Science Creates is the host incubator for Extracellular's Bristol headquarters. Provides infrastructure, facilities, and ecosystem support for biotech startups. Extracellular is based at and supported by Science Creates in Bristol.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborated to produce low-cost, license-free cell banks relevant to the cultivated meat industry. This collaboration enables research organisations across the UK and globally to use these cells to develop better cultivated meat products.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1The Cultured Hub
TypeDirect peer
Description

Dutch CDMO dedicated to cellular agriculture scale-up, offering pilot-scale bioprocessing services for cultivated meat and precision fermentation companies. Directly comparable as one of the few dedicated cellular agriculture CDMOs in Europe.

2Culture Biosciences
TypeDirect peer
Description

US-based contract bioprocess development company operating smart bioreactor facilities with high-throughput process optimization for synbio and cellular agriculture customers. Comparable service model (CDMO/bioprocess development) and target customer base in synthetic biology.

TypeBroad incumbent
Description

Large US synthetic biology platform offering cell engineering and biomanufacturing services across food, agriculture, and industrial biotech verticals. Broad incumbent with overlapping capabilities in cellular agriculture, though focused upstream on strain engineering rather than downstream food-grade manufacturing.

TypeEmerging player
Description

China/US biomanufacturing platform combining synthetic biology, strain engineering, and process scale-up for food, beauty, and industrial applications. Emerging player with partial overlap in cellular agriculture bioprocessing and a comparable customer focus on alternative proteins.

TypeOthers
Description

Global pharma and biotech CDMO with extensive mammalian cell culture capabilities across scales and regulatory expertise. Broad incumbent whose existing biopharma CDMO platform could pivot to cellular agriculture services if the market matures, representing a significant potential competitive threat.

TypeEmerging player
Description

Netherlands-based protein engineering platform using AI/ML to design and optimize bioprocesses for synbio applications including food and industrial biotech. Emerging player with overlapping bioprocess optimization capability, though focused more on computational design than physical pilot-scale manufacturing.

TypeBroad incumbent
Description

Major global CDMO with biologics manufacturing capabilities across scales and modalities. Broad incumbent whose mammalian cell culture expertise and global footprint represent a potential competitive threat if they extend into cellular agriculture CDMO services.

TypeBroad incumbent
Description

Large-scale Korean CDMO offering biologics contract manufacturing with significant bioreactor capacity and mammalian cell expertise. Broad incumbent representing potential competitive threat if they enter cellular agriculture services given their existing scale and capital base.

TypeOthers
Description

UK-based producer of low-cost growth media for cultivated meat, a complementary ecosystem player to Extracellular's process development and manufacturing services. Related but not directly competitive — Multus supplies inputs while Extracellular uses them in scale-up services.

TypeEmerging player
Description

US-based AI-driven protein discovery and biomanufacturing company serving food and personal care customers with novel functional ingredients. Emerging player with partial overlap in food/cellular agriculture bioprocessing, though more focused on ingredient discovery than pilot-scale CDMO services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Extracellular

Bioprocessing CDMO Servicesextracellular.com

Extracellular is a Bristol-based CDMO providing bioprocessing and scale-up services for cell-cultivated meat, seafood, plant cell ingredients, cosmetics, and bio-materials companies, operating Europe's largest dedicated pilot facility to bridge R&D and commercial production.

What Extracellular does

Extracellular is a Bristol, UK-based contract development and manufacturing organization (CDMO) founded in 2021 by Will Milligan, dedicated to supporting the cellular agriculture industry through bioprocessing and scale-up services for animal and plant cell-cultivated products. The company serves startups and enterprises developing cultivated meat, seafood, plant-cell-derived ingredients (cocoa, coffee, saffron), cosmetics actives (cell lysate, exosomes), and bio-materials (cultivated leather, cotton, wood), addressing the 'valley of death' between R&D and commercial production by eliminating the need for customers to build their own pilot facilities. Its technology platform combines proprietary continuous perfusion and repeated fed-batch processes delivering industry-leading 380g/L+ yields, a high-throughput screening platform capable of evaluating up to 1,000 media or cell conditions, and parallel bioreactor optimization using 12-24 units to compress process development timelines.

The company operates Europe's largest dedicated contract pilot facility for cell-cultivated products at its 9,000 ft² Bristol site within the Science Creates incubator, with bioreactor capacities ranging from 50L to 2,000L and planned expansion to 8,000L total capacity (up to 100 tons/year). Extracellular holds ISO 22000 food safety management, ISO 9001:2015 quality management, and Cyber Essentials Plus certifications, and is registered as a UK Food Business with the FSA and FSS, enabling regulated taste trials for novel cell-cultivated foods. Revenue is generated through five service lines (Contract Manufacturing, Process Development, Media Development, Cell Line Development, and Consultancy) sold via direct enterprise sales on a quote-based, multi-year contract pricing model. The company has served 20+ customers across 8 countries and 4 continents, with named engagements including Merck Life Science and Meatly, and is supported by strategic partnerships with Big Idea Ventures, Vevolution, Roslin Technologies, Nutreco, and Innovate UK.

Extracellular firmographics

Firmographics
Name
Extracellular
Legal name
Extracellular
Website
https://extracellular.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Extracellular is a Bristol-based CDMO providing bioprocessing and scale-up services for cell-cultivated meat, seafood, plant cell ingredients, cosmetics, and bio-materials companies, operating Europe's largest dedicated pilot facility to bridge R&D and commercial production.
Ownership category
akta.pro rank

Extracellular industry classification

Industry
Product category
Bioprocessing CDMO Services
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
General Industrial Machinery & Equipment, Nec (3569)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cultivated meat CDMO
  • Bioprocessing services
  • Cell line development
  • Media optimization services
  • Contract manufacturing

Where Extracellular is headquartered

Location

Headquarters

HQ city
Bristol
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Extracellular business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Contract Manufacturing: Scale-up and contract manufacturing services up to 2,000L bioreactor scale within purpose-built food-grade facilities. Customers pay for manufacturing capacity and production services.
  2. Process Development Services: Optimization and scale-up of manufacturing processes using plant and animal cells. Includes parallel bioreactors for high-throughput optimization, process intensification, and scalability studies.
  3. Media Development Services: High-throughput media optimisation for cost, quality and regulatory compliance, including serum replacement and cost optimization studies.
  4. Cell Line Development Services: Established workflows for adherent and suspension cell lines including cell isolation, monoclonal cell lines, cell banking, and suspension adaptation.
  5. Consultancy Services: Technology assessment, manufacturability and cost modelling for novel bio-based products including commercial strategy, technology landscape analysis, and due diligence support.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for CDMO services

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Extracellular product offering

Product offering

Core offering

Extracellular is a contract development and manufacturing organisation (CDMO) providing bioprocessing and scale-up services for cell-cultivated products. The company offers five core service lines — Contract Manufacturing (up to 2,000L bioreactor scale), Process Development, Media Development, Cell Line Development, and Consultancy — targeting cultivated meat, seafood, plant cell culture, cosmetics, and bio-materials companies. All services are delivered from purpose-built food-grade facilities in Bristol, UK.

Product overview

Extracellular is a CDMO (contract development and manufacturing organisation) offering five interconnected service lines covering the full product development lifecycle. The three development-focused services—Process Development, Media Development, and Cell Line Development—handle R&D projects across cell-line development, media optimization, and process engineering. The two commercial-stage services—Contract Manufacturing and Consultancy Services—provide infrastructure and expertise for production at scale and strategic guidance on market entry. All services support the company's three market focus areas: Food & Nutrition (cultivated meat, seafood, plant cell culture), Personal Care & Cosmetics (plant cell derived ingredients), and Materials (cultivated leather, cotton, wood). The company operates purpose-built facilities in Bristol, UK, with bioreactor capabilities from 1L to 2,000L.

Differentiator

Problem solved

Functional benefit

Products and services

  • Contract Manufacturing Scale-up and contract manufacturing services up to 2,000L within purpose-built facilities, providing commercial production, material supply for product evaluation, and scalability validation for cell-cultivated product companies in food, cosmetics, and materials sectors.
  • Process Development Optimization and scale-up of manufacturing processes using plant and animal cells, featuring parallel bioreactors for high-throughput optimisation, process intensification, and support for continuous, semi-continuous, and fed-batch processes.
  • Media Development High-throughput media optimisation for cost, quality and regulatory compliance, including high-throughput screening, animal serum component replacement, cost optimisation, and media stability studies for cell-cultivated products.
  • Cell Line Development Established workflows for adherent and suspension cell lines to optimize growth and productivity, including cell isolation, monoclonal cell lines, cell banking, and suspension adaptation for cultivated meat and other cell-cultivated products.
  • Consultancy Services Technology assessment, manufacturability and cost modelling for novel bio-based products, including commercial strategy, cost of goods modelling, technology landscape analysis, and due diligence support for companies developing cell-cultivated products.

Quantifiable outcome

  • Up to 70% reduction in costs and timelines for media scaling projects (200L scale in 5 months)
  • +3 more outcomes

Companies that use Extracellular

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Extracellular technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Extracellular partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Roslin TechnologiescoreStrategic or Co-development PartnerCo-presenting at the 2025 NAPIC Inaugural Conference on process innovations. Collaboration includes developing scalable, robust production platforms for cell cultivated products leveraging continuous perfusion and repeated fed-batch processes. Joint poster presentation showcasing complementary approaches to scalable manufacturing.
  • Merck Life SciencecoreTechnology or IntegrationStrategic partnership to scale Merck's serum-free media formulation to 200L using fed-batch process. Successfully produced kilograms of cultivated meat, demonstrating both Merck's high-performance media and Extracellular's pilot scale capabilities. Partnership highlighted at MEVO Conference 2024 in Barcelona.
  • Science CreatescoreStrategic or Co-development PartnerScience Creates is the host incubator for Extracellular's Bristol headquarters. Provides infrastructure, facilities, and ecosystem support for biotech startups. Extracellular is based at and supported by Science Creates in Bristol.
  • Multus BiotechnologyminorStrategic or Co-development PartnerCollaborated to produce low-cost, license-free cell banks relevant to the cultivated meat industry. This collaboration enables research organisations across the UK and globally to use these cells to develop better cultivated meat products.

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Extracellular competitors and assessment

Company assessment

Direct peers

  • The Cultured Hub: Dutch CDMO dedicated to cellular agriculture scale-up, offering pilot-scale bioprocessing services for cultivated meat and precision fermentation companies. Directly comparable as one of the few dedicated cellular agriculture CDMOs in Europe.
  • Culture Biosciences: US-based contract bioprocess development company operating smart bioreactor facilities with high-throughput process optimization for synbio and cellular agriculture customers. Comparable service model (CDMO/bioprocess development) and target customer base in synthetic biology.

Broad incumbents

  • Ginkgo Bioworks: Large US synthetic biology platform offering cell engineering and biomanufacturing services across food, agriculture, and industrial biotech verticals. Broad incumbent with overlapping capabilities in cellular agriculture, though focused upstream on strain engineering rather than downstream food-grade manufacturing.
  • Catalent: Major global CDMO with biologics manufacturing capabilities across scales and modalities. Broad incumbent whose mammalian cell culture expertise and global footprint represent a potential competitive threat if they extend into cellular agriculture CDMO services.
  • Samsung Biologics: Large-scale Korean CDMO offering biologics contract manufacturing with significant bioreactor capacity and mammalian cell expertise. Broad incumbent representing potential competitive threat if they enter cellular agriculture services given their existing scale and capital base.

Emerging players

  • Bota Bio: China/US biomanufacturing platform combining synthetic biology, strain engineering, and process scale-up for food, beauty, and industrial applications. Emerging player with partial overlap in cellular agriculture bioprocessing and a comparable customer focus on alternative proteins.
  • Cradle Bio: Netherlands-based protein engineering platform using AI/ML to design and optimize bioprocesses for synbio applications including food and industrial biotech. Emerging player with overlapping bioprocess optimization capability, though focused more on computational design than physical pilot-scale manufacturing.
  • Shiru: US-based AI-driven protein discovery and biomanufacturing company serving food and personal care customers with novel functional ingredients. Emerging player with partial overlap in food/cellular agriculture bioprocessing, though more focused on ingredient discovery than pilot-scale CDMO services.

Others

  • Lonza: Global pharma and biotech CDMO with extensive mammalian cell culture capabilities across scales and regulatory expertise. Broad incumbent whose existing biopharma CDMO platform could pivot to cellular agriculture services if the market matures, representing a significant potential competitive threat.
  • Multus Biotechnology: UK-based producer of low-cost growth media for cultivated meat, a complementary ecosystem player to Extracellular's process development and manufacturing services. Related but not directly competitive — Multus supplies inputs while Extracellular uses them in scale-up services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Extracellular social profiles

Digital presence

Extracellular compliance and trust

Trust signal

Compliance4 records

Extracellular financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Extracellular leadership team

Management profile

Number of profiles

Profiles6 records

Extracellular funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Extracellular M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Extracellular

What does Extracellular do?

Extracellular is a contract development and manufacturing organisation (CDMO) providing bioprocessing and scale-up services for cell-cultivated products. The company offers five core service lines — Contract Manufacturing (up to 2,000L bioreactor scale), Process Development, Media Development, Cell Line Development, and Consultancy — targeting cultivated meat, seafood, plant cell culture, cosmetics, and bio-materials companies. All services are delivered from purpose-built food-grade facilities in Bristol, UK.

Is Extracellular a public or private company?

Extracellular is a private company. It is classified as venture growth investor backed and is currently operating.

When was Extracellular founded?

Extracellular was founded in 2021. It employs 11 to 50 people.

Where is Extracellular based?

Extracellular is headquartered in Bristol, United Kingdom, in the Europe region.

How does Extracellular make money?

Five revenue lines are on record. Contract Manufacturing is the primary driver. The others are process Development Services, media Development Services, cell Line Development Services and consultancy Services.

Who are Extracellular's main competitors?

Direct peers on record are The Cultured Hub and Culture Biosciences. Broad incumbents are Ginkgo Bioworks, Catalent and Samsung Biologics. Emerging players are Bota Bio, Cradle Bio and Shiru. Others are Lonza and Multus Biotechnology.

Does Extracellular have an API?

No public API is recorded for Extracellular.

What industry is Extracellular in?

Extracellular's product category is Bioprocessing CDMO Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 3254 and its SIC code is 3569.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GreenqueenFork & Good Partners with Nutreco & Extracellular for Affordable, Scalable Cultivated MeatCultivated meat startup Fork & Good has entered a strategic collaboration with animal feed company Nutreco and biotech manufacturer Extracellular to scale production of beef and pork while reducing costs. The partnership aims to develop efficient media formulations and streamline supply chains, building on Fork & Good's recent acquisition of Orbillion Bio to expand its global footprint. The companies are targeting commercial viability by driving down biomass costs to parity with commodity pork.ProteinproductiontechnologyFork & Good, Extracellular and Nutreco form strategic partnership to accelerate cultivated meat scale-upFork & Good, Extracellular, and Nutreco have formed a strategic partnership to accelerate the scale-up of cultivated meat production through improved media formulations and biomanufacturing capabilities. The collaboration aims to address key economic and supply-chain challenges by leveraging each company's expertise in production systems, contract manufacturing, and cell feed inputs. This joint effort seeks to facilitate commercial-scale deployment and regulatory acceptance of sustainable protein options.VevolutionExtracellular Secures Funding on Vevolution to Accelerate Cultivated Meat industryExtracellular, a cultivated meat development partner based in the United Kingdom, has secured over $1.9 million in funding to accelerate its scale-up capabilities and production infrastructure. The investment was facilitated by Vevolution and includes contributions from Future Food Fund, Big Idea Ventures, and other investors to support the expansion of bioreactor operations. This capital injection aims to address industry challenges in scaling cellular agriculture manufacturing as regulatory approvals remain limited primarily to Singapore.ExtracellularBig Idea Ventures Announces Investment in ExtracellularBig Idea Ventures has announced a pre-seed investment in UK-based scale-up Extracellular as part of its bi-annual new protein accelerator program. The funding was provided through the firm's New Protein Fund I, which manages over $50 million in assets under management. Extracellular will utilize this capital to accelerate its work in cultivated meat and seafood as a contract development and manufacturing organization (CDMO).